Provided by Tiger Trade Technology Pte. Ltd.

Tiziana Life Sciences PLC

1.11
+0.156316.39%
Post-market: 1.10-0.0100-0.90%19:56 EDT
Volume:1.52M
Turnover:1.64M
Market Cap:140.97M
PE:-7.12
High:1.14
Open:0.9950
Low:0.9667
Close:0.9537
52wk High:2.33
52wk Low:0.7615
Shares:127.00M
Float Shares:64.88M
Volume Ratio:2.13
T/O Rate:2.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1558
EPS(LYR):-0.1558
ROE:-924.32%
ROA:-115.96%
PB:2710.96
PE(LYR):-7.12

Loading ...

Tiziana Reports up to 34% Drop in Brain Inflammation in Third MSA Patient on Intranasal Foralumab in Phase 2 Trial

Reuters
·
Jul 31

Tiziana Life Sciences - Third MSA Patient Shows up to 34% Reduction in SUV and 26% in Suvr in Brain Regions

THOMSON REUTERS
·
Jul 31

Tiziana Life Sciences - to Continue Evaluating Intranasal Foralumab in Additional MSA Patients

THOMSON REUTERS
·
Jul 31

Tiziana Life Sciences CEO Ivor Elrifi Files Initial Beneficial Ownership Statement

Reuters
·
Jul 24

Tiziana Life Sciences Chairman Cerrone Raises Stake to 34.93% After Buying 42,357 Shares at $0.99

Reuters
·
Jul 22

Tiziana Life Sciences Completes First Dosing in Phase 2 Inform-ms Trial of Intranasal Foralumab in Secondary Progressive MS

Reuters
·
Jun 25

Tiziana Announces Last Patient Successfully Dosed in Its Phase 2 Inform-ms Trial

THOMSON REUTERS
·
Jun 25

Tiziana Life Sciences - Topline Data from Inform-ms Trial Expected Late Q3 or Early Q4 2026

THOMSON REUTERS
·
Jun 25

Tiziana Life Sciences Executive Chairman Gabriele Cerrone Increases Holdings

MT Newswires Live
·
Jun 15

Tiziana Life Sciences’ COO and CFO Keeren Shah files initial beneficial ownership statement

Reuters
·
May 23

Tiziana Life Sciences Completes Patient Enrollment for Phase 2a Multiple Sclerosis Trial

MT Newswires Live
·
May 21

Tiziana fully enrolls Phase 2 placebo-controlled MS trial

TIPRANKS
·
May 21

Tiziana completes enrollment in Phase 2a intranasal foralumab trial in secondary progressive MS

Reuters
·
May 21

Tiziana Fully Enrolls Its Phase 2 Placebo Controlled Multiple Sclerosis Trial

THOMSON REUTERS
·
May 21

Sector Update: Healthcare Stocks Rise Tuesday Afternoon

MT Newswires Live
·
May 20

Tiziana Life Sciences announces updated intranasal foralumab data

TIPRANKS
·
May 19

Tiziana Life Sciences Says Multiple Sclerosis Therapy Shows Tolerability, Fatigue Improvement in Updated Clinical Data

MT Newswires Live
·
May 19

Tiziana reports positive expanded-access data for intranasal foralumab in non-active SPMS

Reuters
·
May 19

Tiziana Life Sciences Ltd - Foralumab Well Tolerated With No New Safety Signals Identified

THOMSON REUTERS
·
May 19

Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis

THOMSON REUTERS
·
May 19